Table 1
Baudax Bio Reports First Quarter Financial Results and Provides Business Update
May 12, 2023 08:32 ET | Baudax Bio, Inc.
Announced Positive Top-Line Final Results from Phase 2 Randomized Clinical Trial of BX1000 Hosted Key Opinion Leader Webinar to Highlight Potential of BX1000 and Neuromuscular Blocking Agent...
baudax bio.jpg
Baudax Bio to Present at the Sidoti Virtual Investor Conference
May 03, 2023 16:05 ET | Baudax Bio, Inc.
MALVERN, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today...
baudax bio.jpg
Baudax Bio Announces Closing of $4 Million Public Offering
May 01, 2023 17:43 ET | Baudax Bio, Inc.
MALVERN, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related...
baudax bio.jpg
Baudax Bio Announces Pricing of $4 Million Public Offering
April 26, 2023 21:15 ET | Baudax Bio, Inc.
MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a pharmaceutical company focused on innovative products for hospital and related...
baudax bio.jpg
Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
April 25, 2023 08:00 ET | Baudax Bio, Inc.
All Patients in Three BX1000 Treatment Cohorts Met Criteria for Good or Excellent Intubation Conditions at 60 Seconds Results to be Discussed in Key Opinion Leader Webinar Today at 10:00am Eastern...
baudax bio.jpg
Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
April 24, 2023 16:30 ET | Baudax Bio, Inc.
MALVERN, Pa., April 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today...
baudax bio.jpg
Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
March 27, 2023 08:00 ET | Baudax Bio, Inc.
41 Subjects Meet Criteria for Good or Excellent Intubation Conditions at 60 Seconds Top Line Results Expected Late April/Early May MALVERN, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Baudax Bio,...
baudax bio.jpg
Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
February 23, 2023 08:00 ET | Baudax Bio, Inc.
Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1...
baudax bio.jpg
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
January 24, 2023 08:00 ET | Baudax Bio, Inc.
MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the...
baudax bio.jpg
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
December 08, 2022 08:00 ET | Baudax Bio, Inc.
MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and related settings, today announced the...